AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30607985
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation therapy (VRT)
Trial: 27510395
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg over 10 minutes followed by a 0.5 μg/kg/hr infusion)
Trial: 27510395
Drug: Fentanyl (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.0 μg/kg over 1 minute followed by a 0.4 μg/kg/hr infusion)
Trial: 27510395
Drug: Remifentanil (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1.0 μg/kg over 1 minute followed by a 0.08 μg/kg/min infusion)
Trial: 20033417
Drug: Organically produced
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organically produced apples (500 g/day for 4 weeks)
Trial: 20033417
Drug: Conventionally produced
RxNorm normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally produced apples (500 g/day for 4 weeks)
Trial: 18525384
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of green tea
Trial: 10431942
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of caffeine
Trial: 8735325
Drug: Blood samples
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples drawn from heparinized double-lumen Hickman catheters after discarding 5, 10, 15, 20, and 25 ml of blood.
Trial: 1836921
Drug: SmithKline Beecham's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SmithKline Beecham's recombinant DNA (SB rDNA) vaccine (Engerix‐B) at its adult dose of 20 micrograms
Trial: 1836921
Drug: MSD rDNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSD rDNA vaccine
Trial: 6407361
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (IVm) - 10 mg of morphine sulfate in 10 ml of saline
Trial: 6407361
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (Em) - 10 mg of morphine sulfate in 10 ml of saline
Trial: 25269764
Drug: Trigger Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger Point Manual Therapy (TrP MT)
Trial: 19669016
Drug: Methadone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.1 mg.kg‐1)
Trial: 19669016
Drug: Clonidine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2.0 (1/4)g.kg‐1)
Trial: 2643046
Drug: Prednisone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (45 mg per square meter of body-surface area, given on alternate days for six months)
Trial: 29575037
Drug: PMBL® Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMBL® Tablet
Trial: 26335635
Drug: HIV nosode
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV nosode (30c potency pills), administered orally once a week for 4 weeks
Trial: 26335635
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical pills), administered orally once a week for 4 weeks
Trial: 17563395
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/d)
Trial: 16990386
Drug: Eculizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (600 mg weekly for 4 weeks, followed by 900 mg one week later and then 900 mg every other week through week 26)
Trial: 15316551
Drug: Rotary preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotary preparations
Trial: 8355458
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (Totamine, 6 to 8 mg/kg/min for 90 to 120 min)
Trial: 8355458
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (Totamine) with perindoprilat (2 mg i.v.)
Trial: 8355458
Drug: Perindoprilat (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat (2 mg i.v.) alone
Trial: 8355458
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (Totamine)
Trial: 8355458
Drug: Perindoprilat (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat (2 mg i.v.)
Trial: 2451409
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose bunazosin (3 mg/day for the first week followed by 4.5 mg/day for the next three weeks)
Trial: 2451409
Drug: Middle dose
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dose bunazosin (1.5 mg/day for the first week to 3.0 mg/day for the next three weeks)
Trial: 2451409
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose bunazosin (0.15 mg/day for the first week to 1.5 mg/day for the next three weeks)
Trial: 2451409
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.125 mg/day for the entire four weeks)
Trial: 16644023
Drug: Mitoxantrone (MX)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (MX) therapy
Trial: 12729289
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements 2 ng/kg/day (group IA)
Trial: 12729289
Drug: Iron syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron syrup 6 mg/kg/day (group II)
Trial: 11220944
Drug: Multimodal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal approach including spinal or spinal-epidural anesthesia, preoperative epidural opioid analgesics, and administration of drugs affecting NMDA receptors (ketamine, magnesium sulfate)
Trial: 8973523
Drug: Rhesus tetravalent
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus tetravalent rotavirus vaccine (RRV‐TV)
Trial: 8973523
Drug: Serotype G1
RxNorm normalized name: Rotavirus serotype G1 Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype G1 monovalent rotavirus vaccine (RRV‐S1)
Trial: 8973523
Drug: Post-vaccination neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-vaccination neutralizing antibody titers to Wa
Trial: 1349112
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg twice daily
Trial: 1349112
Drug: Parenteral combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral combination antibiotics (amikacin 15 mg/kg daily, plus carbenicillin, cloxacillin, or piperacillin)
Trial: 30131229
Drug: Scheduled repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled repetitive 24‐hour levosimendan infusions (LEVO) at tailored doses (0.05‐0.2 μg/kg/min)
Trial: 27467714
Drug: Baclofen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30 mg/day for 3 months)
Trial: 18764999
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg letrozole
Trial: 11856089
Drug: OAC250 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC250 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Trial: 11856089
Drug: OAC500 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC500 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Trial: 11856089
Drug: OTC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC group (omeprazole 20 mg, tinidazole 500 mg, clarithromycin 500 mg)
Trial: 7776513
Drug: Diltiazem 4
RxNorm normalized name: dilTIAZem 420 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 4 mcg.kg‐1.min‐1 constant infusion
Trial: 7776513
Drug: Diltiazem 2
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 2 mcg.kg‐1.min‐1 constant infusion
Trial: 30922154
Drug: PHYLLPRO™, 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHYLLPRO™, 750 mg/day for 10 days
Trial: 23522182
Drug: AZD1656 (40-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (40-200 mg)
Trial: 23522182
Drug: AZD1656 (20-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (20-140 mg)
Trial: 23522182
Drug: AZD1656 (10-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (10-80 mg)
Trial: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) once daily (400 mg/day, 250 mg/day if body weight <60 kg)
Trial: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) twice daily (400 mg/day, 250 mg/day if body weight <60 kg)
Trial: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) once daily and twice daily
Trial: 6496450
Drug: 3 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 micrograms doses of heat-inactivated hepatitis B surface antigen (HBsAg) at one-month intervals (trial A)
Trial: 6496450
Drug: 5 different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 different dosages of the vaccine (trial B)
Trial: 30215690
Drug: Teprotumumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab, a monoclonal inhibitory antibody targeting IGF‐IR
Trial: 29606129
Drug: Life Steps-Drug
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Life Steps-Drug Use (LS-DU) intervention
Trial: 20530110
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with heparin (0.5 IU/ml)
Trial: 20530110
Drug: TPN without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN without heparin
Trial: 18842911
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids treatment based on eNO and sEos levels
Trial: 18842911
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment based on symptoms and function
Trial: 7723340
Drug: Allopurinol 200
RxNorm normalized name: allopurinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 200 mg intravenously 1 hour preoperatively
Trial: 28110424
Drug: Caffeine group
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine group (n = 15), coffee containing 222 mg of caffeine 2 hours before catheterization
Trial: 27273884
Drug: Cycle Ergometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle Ergometry (CE) with 10 g protein/46 g carbohydrate drink (223 kcal)
Trial: 27273884
Drug: Combat rations
RxNorm normalized name: Provita Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combat rations supplemented with 1000 kcal/day from 20 g protein- or 48 g carbohydrate-based bars
Trial: 20345030
Drug: Fixed-point spin
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-point spin reduction of spinal manipulation therapy
Trial: 20345030
Drug: Dialectical prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical prescription
Trial: 18631903
Drug: MPT-OA plus
RxNorm normalized name: MPT-0L055
DrugBank: MPT-0L055 (DB17136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPT-OA plus standard treatment
Trial: 12362781
Drug: Micro-encapsulated ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-encapsulated ferrous fumarate (12.5 mg of elemental iron)
Trial: 10355573
Drug: Further chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further chemotherapy (3 courses of MIP: cisplatin 50 mg/m2, ifosfamide 3 g/m2, mitomycin C 6 mg/m2)
Trial: 2792112
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nicardipine
Trial: 7732981
Drug: Open-label nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label nicardipine (30 or 40 mg three times a day for 1 week)
Trial: 1975199
Drug: Atipamezole 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole 100 mg i.v.
Trial: 1975199
Drug: Atipamezole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole 30 mg i.v.
Trial: 1975199
Drug: Atipamezole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole 10 mg i.v.
Trial: 1975199
Drug: Atipamezole (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole (oral dosing)
Trial: 25709097
Drug: Δ(9)‐THC 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9)‐THC 0.03 mg/kg
Trial: 25709097
Drug: Δ(9)‐THC 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9)‐THC 0.015 mg/kg
Trial: 17484218
Drug: Live pentavalent
RxNorm normalized name: rotavirus, live pentavalent (RV5) Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live pentavalent rotavirus vaccine (PRV)
Trial: 15754631
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m2 daily for 5 days, repeated 5 times with 21-day intervals)
Trial: 11586196
Drug: Laparoscopic skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic skills training (30 minutes daily for 10 days)
Trial: 9704732
Drug: VACOP-B for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACOP-B for 12 weeks plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT)
Trial: 7988262
Drug: Preoperative mitomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative mitomycin, vinblastine, and cisplatin (MVP) chemotherapy (cisplatin 120 mg/m2, mitomycin 8 mg/m2 on day 1 + 29, vinblastine 4.5 mg/m2 on days 1, 15, 22, and 29, and 2.0 mg/m2 on day 8)
Trial: 31923105
Drug: Active tACS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tACS (20 daily 40-min sessions at 77.5 Hz, 15 mA)
Trial: 31634198
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir disoproxil fumarate (TDF) for pre‐exposure prophylaxis (PrEP)
Trial: 26231324
Drug: Coaching about
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching about dietary and medication adherence
Trial: 20218321
Drug: Qianliean Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianliean Suppository (1 pill per night for 28 days)
Trial: 20218321
Drug: Yejuhua Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yejuhua Suppository (1 pill per night for 28 days)
Trial: 20218321
Drug: Qianliean Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianliean Suppository
Trial: 20218321
Drug: Yejuhua Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yejuhua Suppository
Trial: 3124680
Drug: Zidovudine (AZT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (AZT), 200 or 250 mg every 4 hours
Trial: 26999045
Drug: Antibiotic-impregnated central
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated central venous catheters (CVCs)
Trial: 17851757
Drug: Tipifarnib 300
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib 300 mg (TL)
Trial: 17851757
Drug: Placebo (L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (L)
Trial: 10633513
Drug: 40% nitrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% nitrous oxide/60% oxygen inhalation
Trial: 10633513
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen inhalation
Trial: 8602667
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(-1) edrophonium
Trial: 2368149
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (cyclosporine and steroids)
Trial: 2368149
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (cyclosporine in lower initial dose, azathioprine, and steroids)
Trial: 99235
Drug: IV hyperalimentation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV hyperalimentation (IVH) administered before and after the first course of CIA for a total of 31 days
Trial: 28464887
Drug: SBIRT Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT Condition with face-to-face, tailored counseling focusing on child's illness, reducing child SHSe, caregiver smoking cessation, and nicotine replacement therapy option.
Trial: 26120056
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine infusion (10 μg/kg/h)
Trial: 24930359
Drug: Varenicline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (titrated up to 1 mg)
Trial: 21818622
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 50 U/Kg of rHuEPO
Trial: 17764013
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata extract (BSE) 400 mg three times daily for 6 weeks
Trial: 17764013
Drug: Open-label BSE
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label BSE therapy
Trial: 15226088
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (alpha-tocopherol acetate, 400 mg/day)
Trial: 9818751
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g bd
Trial: 9818751
Drug: Imipenem‐cilastatin 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem‐cilastatin 1 g tds (50 mg/kg/day)
Trial: 8110569
Drug: 5% EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% EMLA cream 2.5 g for 30 min
Trial: 8110569
Drug: 5% EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% EMLA cream 2.5 g for 60 min
Trial: 8110569
Drug: amethocaine cream
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amethocaine cream 1 g (5% w/w) for 30 min
Trial: 8110569
Drug: amethocaine cream
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amethocaine cream 1 g (5% w/w) for 60 min
Trial: 23733232
Drug: Alphacypermethrin (ACYP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphacypermethrin (ACYP) pour-on treatment
Trial: 20066735
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Trial: 20066735
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^7, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Trial: 20066735
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Trial: 20066735
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9
Trial: 19363849
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of perindopril-indapamide
Trial: 19648155
Drug: 0 ng
RxNorm normalized name: ALCOHOL 80 ng in 100 mL TOPICAL SPRAY [PSR Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ng ml(‐1) remifentanil
Trial: 19648155
Drug: 2 ng
RxNorm normalized name: VITAMIN A ACETATE 700 ug / THIAMINE MONONITRATE 1 mg / RIBOFLAVIN 1 mg / NIACINAMIDE 12 mg / PYRIDOXINE HYDROCHLORIDE 1.15 mg / CYANOCOBALAMIN 3.5 ug / LEVOMEFOLATE CALCIUM 250 ug / ASCORBIC ACID 70 mg / CHOLECALCIFEROL 12 ng / .ALPHA.-TOCOPHEROL ACETATE, D- 11.5 mg / SODIUM FLUORIDE 1 mg ORAL TABLET [FloraFol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ng ml(‐1) remifentanil
Trial: 19648155
Drug: 4 ng
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ng ml(‐1) remifentanil
Trial: 11566624
Drug: iNOS specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNOS specific inhibitors